将TSPO-PET成像与代谢组学相结合,提高多发性硬化症的预后准确性。

IF 2.1 Q3 CLINICAL NEUROLOGY
BMJ Neurology Open Pub Date : 2025-04-16 eCollection Date: 2025-01-01 DOI:10.1136/bmjno-2025-001026
Daniel E Radford-Smith, Abi G Yates, Tereza Kacerova, Marjo Nylund, Marcus Sucksdorff, Markus Matilainen, Eline Willemse, Johanna Oechtering, Aleksandra Maleska Maceski, David Leppert, Jens Kuhle, Fay Probert, Daniel C Anthony, Laura Airas
{"title":"将TSPO-PET成像与代谢组学相结合,提高多发性硬化症的预后准确性。","authors":"Daniel E Radford-Smith, Abi G Yates, Tereza Kacerova, Marjo Nylund, Marcus Sucksdorff, Markus Matilainen, Eline Willemse, Johanna Oechtering, Aleksandra Maleska Maceski, David Leppert, Jens Kuhle, Fay Probert, Daniel C Anthony, Laura Airas","doi":"10.1136/bmjno-2025-001026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Predicting disease progression in multiple sclerosis (MS) remains challenging. PET imaging with 18 kDa translocator protein (TSPO) radioligands can detect microglial and astrocyte activation beyond MRI-visible lesions, which has been shown to be highly predictive of disease progression. We previously demonstrated that nuclear magnetic resonance (NMR)-based metabolomics could accurately distinguish between relapsing-remitting (RRMS) and secondary progressive MS (SPMS). This study investigates whether combining TSPO imaging with metabolomics enhances predictive accuracy in a similar setting.</p><p><strong>Methods: </strong>Blood samples were collected from 87 MS patients undergoing PET imaging with the TSPO-binding radioligand <sup>11</sup>C-PK11195 in Finland. Patient disability was assessed using the expanded disability status scale (EDSS) at baseline and 1 year later. Serum metabolomics was performed to identify biomarkers associated with TSPO binding and disease progression.</p><p><strong>Results: </strong>Greater TSPO availability in the normal-appearing white matter and perilesional regions correlated with higher EDSS. Serum metabolites glutamate (p=0.02), glutamine (p=0.006), and glucose (p=0.008), detected by NMR, effectively distinguished future progressors. These three metabolites alone predicted progression with the same accuracy as TSPO-PET imaging (AUC 0.78; p=0.0001), validated in an independent cohort. Combining serum metabolite data with PET imaging significantly improved predictive power, achieving an AUC of 0.98 (p<0.0001).</p><p><strong>Conclusion: </strong>Measuring three specific serum metabolites is as effective as TSPO imaging in predicting MS progression. However, integrating TSPO imaging with serum metabolite analysis substantially enhances predictive accuracy. Given the simplicity and affordability of NMR analysis, this approach could lead to more personalised, accessible treatment strategies and serve as a valuable tool for clinical trial stratification.</p>","PeriodicalId":52754,"journal":{"name":"BMJ Neurology Open","volume":"7 1","pages":"e001026"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004482/pdf/","citationCount":"0","resultStr":"{\"title\":\"Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis.\",\"authors\":\"Daniel E Radford-Smith, Abi G Yates, Tereza Kacerova, Marjo Nylund, Marcus Sucksdorff, Markus Matilainen, Eline Willemse, Johanna Oechtering, Aleksandra Maleska Maceski, David Leppert, Jens Kuhle, Fay Probert, Daniel C Anthony, Laura Airas\",\"doi\":\"10.1136/bmjno-2025-001026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Predicting disease progression in multiple sclerosis (MS) remains challenging. PET imaging with 18 kDa translocator protein (TSPO) radioligands can detect microglial and astrocyte activation beyond MRI-visible lesions, which has been shown to be highly predictive of disease progression. We previously demonstrated that nuclear magnetic resonance (NMR)-based metabolomics could accurately distinguish between relapsing-remitting (RRMS) and secondary progressive MS (SPMS). This study investigates whether combining TSPO imaging with metabolomics enhances predictive accuracy in a similar setting.</p><p><strong>Methods: </strong>Blood samples were collected from 87 MS patients undergoing PET imaging with the TSPO-binding radioligand <sup>11</sup>C-PK11195 in Finland. Patient disability was assessed using the expanded disability status scale (EDSS) at baseline and 1 year later. Serum metabolomics was performed to identify biomarkers associated with TSPO binding and disease progression.</p><p><strong>Results: </strong>Greater TSPO availability in the normal-appearing white matter and perilesional regions correlated with higher EDSS. Serum metabolites glutamate (p=0.02), glutamine (p=0.006), and glucose (p=0.008), detected by NMR, effectively distinguished future progressors. These three metabolites alone predicted progression with the same accuracy as TSPO-PET imaging (AUC 0.78; p=0.0001), validated in an independent cohort. Combining serum metabolite data with PET imaging significantly improved predictive power, achieving an AUC of 0.98 (p<0.0001).</p><p><strong>Conclusion: </strong>Measuring three specific serum metabolites is as effective as TSPO imaging in predicting MS progression. However, integrating TSPO imaging with serum metabolite analysis substantially enhances predictive accuracy. Given the simplicity and affordability of NMR analysis, this approach could lead to more personalised, accessible treatment strategies and serve as a valuable tool for clinical trial stratification.</p>\",\"PeriodicalId\":52754,\"journal\":{\"name\":\"BMJ Neurology Open\",\"volume\":\"7 1\",\"pages\":\"e001026\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004482/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Neurology Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjno-2025-001026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Neurology Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjno-2025-001026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:预测多发性硬化症(MS)的疾病进展仍然具有挑战性。用18 kDa转运蛋白(TSPO)放射性配体进行PET成像可以检测mri可见病变以外的小胶质细胞和星形胶质细胞活化,这已被证明是疾病进展的高度预测。我们之前已经证明,基于核磁共振(NMR)的代谢组学可以准确区分复发缓解型(RRMS)和继发性进展型MS (SPMS)。本研究探讨了TSPO成像与代谢组学相结合是否能提高类似情况下的预测准确性。方法:收集芬兰87例MS患者的血液样本,采用tspo结合放射配体11C-PK11195进行PET成像。在基线和1年后使用扩展残疾状态量表(EDSS)评估患者的残疾。血清代谢组学鉴定与TSPO结合和疾病进展相关的生物标志物。结果:表现正常的白质和病灶周围区域的TSPO可用性越高,EDSS越高。通过核磁共振检测血清代谢物谷氨酸(p=0.02)、谷氨酰胺(p=0.006)和葡萄糖(p=0.008),可以有效地区分未来的进展。这三种代谢物单独预测进展的准确性与TSPO-PET成像相同(AUC 0.78;P =0.0001),在独立队列中得到验证。将血清代谢物数据与PET成像相结合可显著提高预测能力,AUC为0.98 (p)。结论:测量三种特定的血清代谢物与TSPO成像在预测MS进展方面同样有效。然而,将TSPO成像与血清代谢物分析相结合,大大提高了预测的准确性。鉴于核磁共振分析的简单性和可负担性,这种方法可能导致更个性化、更容易获得的治疗策略,并作为临床试验分层的有价值工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis.

Background: Predicting disease progression in multiple sclerosis (MS) remains challenging. PET imaging with 18 kDa translocator protein (TSPO) radioligands can detect microglial and astrocyte activation beyond MRI-visible lesions, which has been shown to be highly predictive of disease progression. We previously demonstrated that nuclear magnetic resonance (NMR)-based metabolomics could accurately distinguish between relapsing-remitting (RRMS) and secondary progressive MS (SPMS). This study investigates whether combining TSPO imaging with metabolomics enhances predictive accuracy in a similar setting.

Methods: Blood samples were collected from 87 MS patients undergoing PET imaging with the TSPO-binding radioligand 11C-PK11195 in Finland. Patient disability was assessed using the expanded disability status scale (EDSS) at baseline and 1 year later. Serum metabolomics was performed to identify biomarkers associated with TSPO binding and disease progression.

Results: Greater TSPO availability in the normal-appearing white matter and perilesional regions correlated with higher EDSS. Serum metabolites glutamate (p=0.02), glutamine (p=0.006), and glucose (p=0.008), detected by NMR, effectively distinguished future progressors. These three metabolites alone predicted progression with the same accuracy as TSPO-PET imaging (AUC 0.78; p=0.0001), validated in an independent cohort. Combining serum metabolite data with PET imaging significantly improved predictive power, achieving an AUC of 0.98 (p<0.0001).

Conclusion: Measuring three specific serum metabolites is as effective as TSPO imaging in predicting MS progression. However, integrating TSPO imaging with serum metabolite analysis substantially enhances predictive accuracy. Given the simplicity and affordability of NMR analysis, this approach could lead to more personalised, accessible treatment strategies and serve as a valuable tool for clinical trial stratification.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Neurology Open
BMJ Neurology Open Medicine-Neurology (clinical)
CiteScore
3.20
自引率
3.70%
发文量
46
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信